Compare STTK & UHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STTK | UHT |
|---|---|---|
| Founded | 2016 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 474.6M | 525.1M |
| IPO Year | 2020 | 1995 |
| Metric | STTK | UHT |
|---|---|---|
| Price | $4.55 | $37.17 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 12 | 0 |
| Target Price | ★ $15.40 | N/A |
| AVG Volume (30 Days) | ★ 841.6K | 86.6K |
| Earning Date | 11-05-2026 | 10-27-2026 |
| Dividend Yield | N/A | ★ 7.82% |
| EPS Growth | ★ 53.02 | N/A |
| EPS | N/A | ★ 1.14 |
| Revenue | $1,000,000.00 | ★ $99,190,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $14.28 | $6.18 |
| P/E Ratio | ★ N/A | $33.39 |
| Revenue Growth | N/A | ★ 0.18 |
| 52 Week Low | $1.89 | $36.07 |
| 52 Week High | $8.33 | $46.30 |
| Indicator | STTK | UHT |
|---|---|---|
| Relative Strength Index (RSI) | 36.78 | 43.57 |
| Support Level | $4.38 | $37.36 |
| Resistance Level | $7.66 | $42.08 |
| Average True Range (ATR) | 0.39 | 0.84 |
| MACD | -0.02 | -0.06 |
| Stochastic Oscillator | 14.29 | 32.14 |
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
Universal Health Realty Income Trust is a healthcare REIT. The company is engaged in the business of investing in and leasing healthcare and human service facilities through direct ownership or through joint ventures, which aggregate into a single reportable segment. The company actively manages a portfolio of healthcare and human service facilities. The revenue and net income are generated from the operation of the investment portfolio, located throughout the United States.